Located in front of Tokiwadai Station, the medical corporation Shin-Ikai Tokiwadai Ekimae Dermatology Clinic is a dermatology clinic with an English-speaking medical care system. It treats a wide range of skin conditions, including atopic dermatitis, eczema, acne, impetigo, herpes zoster, viral warts, moles, corns, calluses, molluscum contagiosum, hives, athlete's foot and fungal nail infections, palmoplantar pustulosis, psoriasis, hyperhidrosis, alopecia areata, and more. For the diagnosis of atopic dermatitis, criteria such as widespread and symmetric rashes, persistence for more than 2 months in infants and more than 6 months in others are used. Treatment follows the guidelines of the Japanese Dermatological Association with moisturizers, anti-inflammatory agents, and anti-allergic agents, and allergy tests are also conducted to identify the cause. Dupilumab, a biologic agent, is adopted as a treatment for severe atopic dermatitis. It suppresses cytokines that cause inflammation, alleviating symptoms resulting from impaired skin barrier function. Dupilumab administration is principally self-injection at home. After the first and second doses are administered and instructed at the clinic, self-injection is performed every 2 or 4 weeks. As it is an expensive biologic agent, the High-Cost Medical Care System may be required. For children, presenting a medical certificate for Tokyo's 23 wards can reduce the burden. As part of initiatives based on the medical DX promotion system enhancement allowance, online billing and online eligibility confirmation for medical information utilization are being promoted, and the introduction of electronic prescriptions and electronic medical record information sharing services is planned. As part of efforts to ensure stable drug supply, generic name prescribing may be used for drugs where generic versions are available. Payment by credit card and electronic settlement is available, and barrier-free facilities are provided.